semaglutide 7.2 mg clinical trial Efficacy and safety of once-weekly 2·0 versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B semaglutide 7.2 mg clinical trial

4.6.2 Retinal disease Diabetic retinopathy (DR) is the most prevalent microvascular complication of diabetes and the leading cause of preventable blindness among working-age individuals (81)

THERAPY NAD+ & NR IV Drips Targeted NAD+ IV therapies designed to enhance cellular energy, mental clarity, metabolic function, and overall vitality

Magnesium citrate earns top recommendation based on mechanism, safety, and user experience

At Wellness Solutions, we are always looking for elevated, science-backed approaches to holistic wellness

As mentioned earlier, Noom Med connects you to a licensed clinician who can assess your health history and determine if prescription GLP-1s or weight-loss medications are right for you